http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-095005-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H3-04 |
| filingDate | 2013-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f195e8a234e27d9787240650415f013a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c905790a6c3c77ee8727ea15f3eac112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a185f8b04a0d2bb5ee624cc3856995d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1c57c22218c197e1cbfc9216686a0af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6abe9c401e12e343f64fbd3a49b4412b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85588fe6b7c55710705edc404a557cb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a6a3a8e8cd784e1a5fef7a0dd2d1b13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be2cf264395026f322e917b681f66ff2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32b94641e1b874cd049982f5a89d087e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aef82020efe21f0906b0d6dabc13059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc0dd006e097d6b19f022f79d6a464fe |
| publicationDate | 2015-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-095005-A1 |
| titleOfInvention | MANOSE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS |
| abstract | The present also provides pharmaceutically acceptable compositions containing the compounds. Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt thereof, wherein V¹ is halogen, NH₂, OH or SH; V is H, halogen, -OR⁷, -NR⁵R⁶, -SR⁷ or aliphatic C₁₋₆; R⁵ is -H; X⁵; Q⁵; X⁵-Q⁵; -C (O) R⁹; -C (O) NHR⁹; or -C (O) OR⁹; R⁶ is -H; X⁶; Q⁶; X⁶-Q⁶; -C (O) R⁹; -C (O) NHR⁹; or -C (O) OR⁹; R⁷ is -H; X⁷; Q⁷; X⁷-Q⁷; -C (O) R⁹; or -C (O) NHR⁹; R⁹ is -H; X⁹; Q⁹; or X⁹-Q⁹; each X⁵, X⁶, X⁷ and X⁹ is, independently, aliphatic C₁₋₆ optionally substituted with 1-3 halo; each Q⁵, Q⁶, Q⁷ and Q⁹ is, independently, C₆₋₁₀ aryl, 5-10 membered heteroaryl, C₃₋₈ cycloaliphatic or 3-12 membered heterocyclyl; wherein said Q⁵, Q⁶, Q⁷ and Q⁹ is, independently, and optionally substituted with 1-6 occurrences of J; Z is a compound of the group of formulas (2); where the rings A, B, C, D, E, F, G, H, I, K, M, N, O, P, Q, R, S, T, U, and, W, X, Y and Z are each, independently, a saturated, completely unsaturated, partially unsaturated or aromatic 5-6 membered monocyclic ring which optionally has 1-4 heteroatoms selected from oxygen, nitrogen or sulfur; a saturated, completely unsaturated, partially unsaturated or aromatic 8-12 membered bicyclic ring that optionally has 1-6 heteroatoms selected from oxygen, nitrogen or sulfur; or a saturated, partially unsaturated or aromatic tricyclic ring of 10-14 members which optionally has 1-6 heteroatoms selected from oxygen, nitrogen or sulfur; L is -X⁼⁼⁼⁼Y-, where X is an aliphatic C₁ or -C (O) - and Y is aliphatic C₁₋₁₀, where up to two methylene units of the aliphatic C₁₋₁₀ are optionally replaced with - C (O) -, NH or NH (aliphatic C₁); L is optionally substituted with 1-3 halo; L¹ is -X¹⁼⁼⁼⁼Y¹- where X¹ is an aliphatic C₁ or -C (O) - and Y¹ is aliphatic C₁₋₁₀, where up to two methylene units of the aliphatic C₁₋₁₀ are optionally replaced with -C (O) -, NH or N (aliphatic C₁₋₆); L¹ is optionally substituted with 1-3 halo; L² is -X²⁼⁼⁼⁼Y²- where X² is an aliphatic C₁ or -C (O) - and Y² is aliphatic C₁₋₁₀, where up to two methylene units of the aliphatic C₁₋₁₀ are optionally replaced with -C (O) -, NH or N (aliphatic C₁₋₆); L² is optionally substituted with 1-3 halo; each L³, L⁵ and L¹⁶ is, independently, aliphatic C₁₋₁₂, where up to three methylene units of the aliphatic C₁₋₁₂ are optionally replaced with -C (O) -, NH or N (aliphatic C₁₋₆); each L³, L⁵ and L¹⁶ is, independently, and is optionally substituted with 1-3 halo; L⁴ is -X⁴⁼⁼⁼⁼Y⁴- where X⁴ is an aliphatic C₁ or -C (O) - and Y⁴ is aliphatic C₁₋₁₀, where up to two methylene units of the aliphatic C₁₋₁₀ are optionally replaced with -C (O) -, NH or N (aliphatic C₁₋₆); L⁴ is optionally substituted with 1-3 halo; L⁶ is aliphatic C₁₋₁₅, where up to six methylene units of the aliphatic C₁₋₁₅ are optionally replaced with O, NH, N (aliphatic C₁₋₆), S, -C (O) -, S (O) or S (O) ₂; L⁶ is optionally substituted with 1-3 halo; each L⁷ and L⁹ is, independently, aliphatic C₁₋₆, where up to two methylene units of the aliphatic C₁₋₆ are optionally replaced with -C (O) -, NH or N (aliphatic C₁₋₄); each L⁷ and L⁹ is, independently, and is optionally substituted with 1-3 halo; L⁸ is -X⁸⁼⁼⁼⁼Y⁸ where X⁸ is an aliphatic C₁ and Y⁸ is aliphatic C₁₋₁₀, where up to two methylene units of the aliphatic C₁₋₁₀ are optionally replaced with -C (O) -, NH or N (aliphatic C₁₋₆); L⁸ is optionally substituted with 1-3 halo; L¹⁰ is aliphatic C₁₋₆ where up to two methylene units of the aliphatic C₁₋₆ are optionally replaced with O, NH, N (aliphatic C₁₋₆), S or -C (O) -; L¹⁰ is optionally substituted with 1-3 halo; L¹¹ is aliphatic C₁₋₆ where up to two methylene units of the aliphatic C₁₋₆ are optionally replaced with O, NH, N (aliphatic C₁₋₆), S or -C (O) -; L¹¹ is optionally substituted with 1-3 halo; L¹² is aliphatic C₁₋₆ where up to two methylene units of the aliphatic C₁₋₆ are optionally replaced with O, NH, N (aliphatic C₁₋₆), S or -C (O) -; L² is optionally substituted with 1-3 halo; L¹³ is aliphatic C₁₋₆ where up to two methylene units of the aliphatic C₁₋₆ are optionally replaced with O, NH, N (aliphatic C₁₋₆), S or -C (O) -; L¹³ is optionally substituted with 1-3 halo; L¹⁴ is -X¹⁴⁼⁼⁼⁼Y¹⁴- where X¹⁴ is an aliphatic C₁ and Y¹⁴ is aliphatic C₁₋₁₀, where up to two methylene units of the aliphatic C₁₋₁₀ are optionally replaced with -C (O) -, NH or N (aliphatic C₁₋₆); L¹⁴ is optionally substituted with 1-3 halo; L¹⁵ is aliphatic C₁₋₆; Every J, JA, JB, JC, JD, JE, JF, JG, JH, JI, JK, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JX, JY and JZ is, independently, halogen, -CN, -NO₂, XJ, QJ or XJ-QJ; or two groups J, JA, JB, JC, JD, JE, JF, JG, JH, JI, JK, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY , or JZ linked to the same carbon atom, together with the carbon atom to which they are attached, optionally form -C = N-OH, -C (O) - or a 3-8 membered saturated monocyclic ring having 0 - 2 heteroatoms selected from oxygen, nitrogen or sulfur; wherein said ring is optionally substituted with 1-3 appearances of halo, CN, oxo, XJ, QJ or XJ-QJ; XJ is an aliphatic C₁₋₁₀, where up to four units of the aliphatic C₁₋₁₀ are optionally replaced with -O-, -NH, N (aliphatic C₁₋₆), -S-, -C (O) -, -C (= NOH) -, -S (O) -, -S (O) ₂-, P or P (O); XJ is optionally substituted with 0-6 occurrences of halo, OH or C₁₋₄ alkyl or is optionally substituted with 0-1 appearances of CN; QJ is a saturated, completely unsaturated, partially unsaturated or aromatic 3-7 membered monocyclic ring that optionally has 1-4 heteroatoms selected from oxygen, nitrogen or sulfur; or a saturated, totally unsaturated, partially unsaturated or aromatic ring of 8-12 members which optionally has 1-6 heteroatoms selected from oxygen, nitrogen or sulfur; wherein each QJ is optionally substituted with 1-6 occurrences of halo, oxo, CN or C₁ alkyl, wherein up to 2 methylene units of said C₁₋₆ alkyl are optionally replaced with -O-, -NH, N (aliphatic C₁ ₋₆), -S-, -C (O) -, -S (O) - or -S (O) ₂-; provided that Z is not CH₂-CH₂, or an element of the formula group (3). |
| priorityDate | 2012-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.